{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:12Z","timestamp":1790855592640,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.blre.2019.100645","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T19:42:39Z","timestamp":1574883759000},"page":"100645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential"],"prefix":"10.1016","volume":"41","author":[{"given":"Mohammad-Hossein","family":"Haddadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensiyeh","family":"Hajizadeh-Saffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Khosravi-Maharlooei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Basiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Negahdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Baharvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100645_bb0005","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100645_bb0010","first-page":"1","article-title":"Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy","author":"Spear","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2019.100645_bb0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T-and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.1500751","article-title":"Chimeric antigen receptor\u2013and TCR-modified T cells enter main street and wall street","volume":"195","author":"Barrett","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0030","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/bloodadvances.2018018556","article-title":"Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo","volume":"2","author":"Parvathaneni","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.100645_bb0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/sj.gt.3300831","article-title":"Impact of chimeric immune receptor extracellular protein domains on T cell function","volume":"6","author":"Patel","year":"1999","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100645_bb0045","first-page":"2945","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"AJT."},{"key":"10.1016\/j.blre.2019.100645_bb0050","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0055","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"128","key":"10.1016\/j.blre.2019.100645_bb0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1182\/blood.V128.22.322.322","article-title":"Targeting FVIII-specific B cells using BAR-transduced regulatory T cells","volume":"2016","author":"Zhang","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0065","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","author":"Maude","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5301\/jo-n.5000035","article-title":"Cancer immunotherapy with chimeric antigen receptor (CAR) T cells","volume":"1","author":"Littman","year":"2017","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.blre.2019.100645_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019321","article-title":"Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis","volume":"7","author":"Grigor","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.blre.2019.100645_bb0080","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors t cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2019.100645_bb0090","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2019.100645_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-015-0091-z","article-title":"Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma","volume":"3","author":"Feng","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2019.100645_bb0100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2019.100645_bb0105","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/j.bbmt.2017.12.558","article-title":"Cytotoxic function of chimeric antigen receptor (CAR) T cells redirected by anti-Muci Nanobody","volume":"24","author":"Rajabzadeh","year":"2018","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1016\/j.blre.2019.100645_bb0110","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2019.100645_bb0115","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.it.2003.08.003","article-title":"T-cell receptor signal transmission: who gives an ITAM?","volume":"24","author":"Pitcher","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0120","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","article-title":"Src family kinases, key regulators of signal transduction","volume":"23","author":"Parsons","year":"2004","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2019.100645_bb0125","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ni.2940","article-title":"Insights into the initiation of TCR signaling","volume":"15","author":"Chakraborty","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0130","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.100645_bb0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100645_bb0140","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar T H 17\/T H 1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell\u2013mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0150","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Th"},{"key":"10.1016\/j.blre.2019.100645_bb0155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PPO.0000000000000034","article-title":"CD28z cars and armored cars","volume":"20","author":"Pegram","year":"2014","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"10.1016\/j.blre.2019.100645_bb0160","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/gen.38.13.09","article-title":"CAR T-cell therapies with a bispecific twist: to bypass antigen escape, TanCAR and NanoCAR therapies take the bispecific route","volume":"38","author":"Zaroff","year":"2018","journal-title":"Genet Eng Biotechn N"},{"key":"10.1016\/j.blre.2019.100645_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2019.100645_bb0175","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2017.021","article-title":"Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells","volume":"28","author":"Siegler","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0180","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-based design of chimeric antigen receptor for T cell engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0185","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther-Nucl Acids"},{"key":"10.1016\/j.blre.2019.100645_bb0190","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.blre.2019.100645_bb0195","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMcibr1608900","article-title":"Modulating immunity to treat autoimmune disease","volume":"375","author":"Amagai","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2019.100645_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.blre.2019.100645_bb0205","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.100645_bb0210","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.blre.2019.100645_bb0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.blre.2019.100645_bb0220","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.autrev.2017.03.009","article-title":"Streptococcus mutans antigen I\/II and autoimmunity in cardiovascular diseases","volume":"16","author":"Lucchese","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100645_bb0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.celrep.2017.09.021","article-title":"Generation of ROR\u03b3t+ antigen-specific T Regulatory 17 cells from Foxp3+ precursors in autoimmunity","volume":"21","author":"Kim","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2019.100645_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1900\/RDS.2014.11.84","article-title":"Islet and stem cell encapsulation for clinical transplantation","volume":"11","author":"Krishnan","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.blre.2019.100645_bb0235","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.tibtech.2018.02.008","article-title":"Antigen-specific Tolerization and targeted delivery as therapeutic strategies for autoimmune diseases","volume":"36","author":"Shakya","year":"2018","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.blre.2019.100645_bb0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0245","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0250","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029041","article-title":"Regulatory T Cells: From Discovery to Autoimmunity","volume":"8","author":"Kitz","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2019.100645_bb0255","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100645_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050038","article-title":"Epigenetic control of the foxp3 locus in regulatory T cells","volume":"5","author":"Floess","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.blre.2019.100645_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2005.02.017","article-title":"In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation","volume":"115","author":"Earle","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1084\/jem.20061852","article-title":"Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease","volume":"204","author":"Lahl","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100645_bb0275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.intimp.2009.01.034","article-title":"Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+ CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys","volume":"9","author":"Ma","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2019.100645_bb0280","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clim.2018.03.008","article-title":"IPEX due to an exon 7 skipping FOXP3 mutation with autoimmune diabetes mellitus cured by selective TReg cell engraftment","volume":"191","author":"Magg","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0285","series-title":"Kidney transplantation, bioengineering and regeneration","first-page":"303","article-title":"Cell therapy in transplantation","author":"McEwen","year":"2017"},{"key":"10.1016\/j.blre.2019.100645_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4+ CD25highCD127-regulatory T cells prolongs survival of pancreatic islets\u2014results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0295","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/pedi.12029","article-title":"Clinical application of regulatory T cells in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.blre.2019.100645_bb0300","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0305","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.4049\/jimmunol.179.7.4685","article-title":"Autoantigen-specific TGF\u03b2-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells","volume":"179","author":"DiPaolo","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0310","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroentrology."},{"key":"10.1016\/j.blre.2019.100645_bb0315","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jnr.20522","article-title":"Decreased FOXP3 levels in multiple sclerosis patients","volume":"81","author":"Huan","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.blre.2019.100645_bb0325","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100645_bb0330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF\u03b1 therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100645_bb0335","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2014.105","article-title":"T REG-cell therapies for autoimmune rheumatic diseases","volume":"10","author":"Miyara","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2019.100645_bb0340","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4049\/jimmunol.200.Supp.176.17","article-title":"Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis","volume":"200","author":"Raffin","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2337\/diabetes.54.1.92","article-title":"Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes","volume":"54","author":"Lindley","year":"2005","journal-title":"Diabetes."},{"key":"10.1016\/j.blre.2019.100645_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev.immunol.19.1.131","article-title":"Tolerance to islet autoantigens in type 1 diabetes","volume":"19","author":"Bach","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0355","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2019.100645_bb0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaut.2016.03.011","article-title":"Regulatory T cell therapy for type 1 diabetes: may the force be with you","volume":"71","author":"Gitelman","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100645_bb0365","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.blre.2019.100645_bb0370","series-title":"Seminars in arthritis and rheumatism","first-page":"149","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","author":"Boleto","year":"2018"},{"key":"10.1016\/j.blre.2019.100645_bb0375","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2019.100645_bb0380","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev.iy.09.040191.002425","article-title":"MHC class-II molecules and autoimmunity","volume":"9","author":"Nepom","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0385","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fimmu.2013.00321","article-title":"MHC class II polymorphisms, autoreactive T-cells, and autoimmunity","volume":"4","author":"Tsai","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0390","article-title":"The role of MHC class II polymorphisms for DM-mediated peptide editing and autoimmunity","volume":"156","author":"Haag","year":"2017","journal-title":"Am Assoc Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0395","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100645_bb0400","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2019.100645_bb0405","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2019.100645_bb0415","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ajt.14202","article-title":"Generating antigen-specific regulatory T cells in the fast lane","volume":"17","author":"Ferreira","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2019.100645_bb0420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaut.2005.03.005","article-title":"Autoantibodies unmasked by redox reactions","volume":"24","author":"McIntyre","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100645_bb0425","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u201cspacer\u201ddomain in the extracellular moiety of chimeric antigen receptors avoids \u201coff-target\u201dactivation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2019.100645_bb0430","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0435","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrrheum.2017.107","article-title":"Antigen-specific immunotherapies in rheumatic diseases","volume":"13","author":"Pozsgay","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2019.100645_bb0440","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2019.100645_bb0445","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1242\/jcs.03234","article-title":"The a3 isoform of V-ATPase regulates insulin secretion from pancreatic \u03b2-cells","volume":"119","author":"Sun-Wada","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.blre.2019.100645_bb0450","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2013.11.004","article-title":"Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?","volume":"150","author":"Jethwa","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into T H 17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100645_bb0460","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.181.4.2277","article-title":"Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-\u03b2-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression","volume":"181","author":"Xiao","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0465","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T H 17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0470","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00296-009-1179-x","article-title":"The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17\/IL-6 secretion in rheumatoid arthritis patients","volume":"30","author":"Yue","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.blre.2019.100645_bb0475","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2337\/diabetes.51.2.339","article-title":"A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice","volume":"51","author":"Gurr","year":"2002","journal-title":"Diabetes."},{"key":"10.1016\/j.blre.2019.100645_bb0480","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","article-title":"IL-6 detection in multiple sclerosis brain","volume":"146","author":"Maimone","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.blre.2019.100645_bb0485","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.4049\/jimmunol.178.11.6725","article-title":"Cutting edge: regulatory T cells induce CD4+ CD25\u2212 Foxp3\u2212 T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-\u03b2","volume":"178","author":"Xu","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9943","article-title":"Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression","volume":"8","author":"Hundhausen","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2019.100645_bb0495","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.4049\/jimmunol.1000788","article-title":"IL-17 immunity in human type 1 diabetes","volume":"185","author":"Honkanen","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0500","doi-asserted-by":"crossref","first-page":"17003","DOI":"10.1074\/jbc.M801286200","article-title":"Foxp3 inhibits ROR\u03b3t-mediated IL-17A mRNA transcription through direct interaction with ROR\u03b3t","volume":"283","author":"Ichiyama","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.100645_bb0505","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.4049\/jimmunol.1100061","article-title":"IL-2 controls the stability of Foxp3 expression in TGF-\u03b2\u2013induced Foxp3+ T cells in vivo","author":"Chen","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0510","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.blre.2019.100645_bb0515","doi-asserted-by":"crossref","first-page":"14023","DOI":"10.1073\/pnas.0806726105","article-title":"TGF-\u03b2 and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3","volume":"105","author":"Samanta","year":"2008","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2019.100645_bb0520","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell."},{"key":"10.1016\/j.blre.2019.100645_bb0525","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/cb3002649","article-title":"Identification of a selective ROR\u03b3 ligand that suppresses Th17 cells and stimulates T regulatory cells","volume":"7","author":"Solt","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.blre.2019.100645_bb0530","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/mol.114.097485","article-title":"Anti-obesity effect of a small molecule repressor of ROR\u03b3","volume":"88","author":"Chang","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.blre.2019.100645_bb0535","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.celrep.2018.02.044","article-title":"IL-23 and IL-1\u03b2 drive human Th17 cell differentiation and metabolic reprogramming in absence of CD28 costimulation","volume":"22","author":"Revu","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2019.100645_bb0540","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4049\/jimmunol.1700920","article-title":"Betaine ameliorates experimental autoimmune encephalomyelitis by inhibiting dendritic cell\u2013derived IL-6 production and Th17 differentiation","volume":"200","author":"Yang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100645_bb0545","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.blre.2019.100645_bb0550","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"How I treat: current concepts in the diagnosis and management of cytokine release syndrome","volume":"5","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0555","series-title":"Front biosci-landmrk","first-page":"2448","article-title":"TGF-beta signal transduction in chronic kidney disease","volume":"14","author":"Schnaper","year":"2009"},{"key":"10.1016\/j.blre.2019.100645_bb0560","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.2741\/gressner","article-title":"Roles of TGF-beta in hepatic fibrosis","volume":"7","author":"Gressner","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.blre.2019.100645_bb0565","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CJI.0b013e318189f13c","article-title":"Tumor derived TGF-Beta mediates conversion of CD4+ Foxp3+ regulatory T cells in a murine model of pancreas cancer","volume":"32","author":"Moo-Young","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.blre.2019.100645_bb0570","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0575","first-page":"703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"4","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100645_bb0580","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.ASN.0000093460.24823.5B","article-title":"Mediators of diabetic renal disease: the case for TGF-\u03b2 as the major mediator","volume":"15","author":"Ziyadeh","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2019.100645_bb0585","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2010.12.004","article-title":"FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents","volume":"32","author":"Ohkura","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.blre.2019.100645_bb0590","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:36Z","timestamp":1759436616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19301596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":118,"alternative-id":["S0268960X19301596"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100645","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100645"}}